Kokoro Eshima Selected Research

DFP-10825

1/2018

Anticancer activity of the intraperitoneal-delivered DFP-10825, the cationic liposome-conjugated RNAi molecule targeting thymidylate synthase, on peritoneal disseminated ovarian cancer xenograft model.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kokoro Eshima Research Topics

Disease

3	Neoplasms (Cancer) 03/2018 - 01/2009
2	Ovarian Neoplasms (Ovarian Cancer) 03/2018 - 01/2018
1	Body Weight (Weight, Body) 03/2018
1	Leukemia 03/2018
1	Ascites 01/2018
1	Hepatocellular Carcinoma (Hepatoma) 01/2009

Drug/Important Bio-Agent (IBA)

2	DNA (Deoxyribonucleic Acid)IBA 03/2018 - 01/2018
2	Pharmaceutical PreparationsIBA 03/2018 - 01/2018
1	Cytarabine (Cytosar-U)FDA LinkGeneric 03/2018
1	CytosineIBA 03/2018
1	DeoxycytidineIBA 03/2018
1	A-Form DNA (A-DNA)IBA 03/2018
1	Gemcitabine FDA Link 03/2018
1	NucleosidesIBA 03/2018
1	DFP-10917IBA 03/2018
1	Liposomes (Liposome)IBA 01/2018
1	DFP-10825IBA 01/2018
1	LuciferasesIBA 01/2018
1	Messenger RNA (mRNA)IBA 01/2018
1	Thymidylate SynthaseIBA 01/2018
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2018
1	Small Interfering RNA (siRNA)IBA 01/2018
1	Interleukin-8 (Interleukin 8)IBA 01/2009
1	RetinoidsIBA 01/2009
1	TAC 101IBA 01/2009
1	Transcription Factor AP-1 (Transcription Factor AP 1)IBA 01/2009